Henderson Morley announces KHV vaccine results


Editor's Picks

Biotechnology company Henderson Morley has announced successful results from its vaccine against the fish disease Koi Herpes Virus (KHV).

Henderson Morley claims that field studies, undertaken by a sub-contracted research facility, have produced 'positive results' with 93% and 96% of vaccinated fish remaining healthy and surviving exposure to KHV.

It is now undertaking further development of two successful vaccine candidates with Schering Plough Animal Health.

Chairman Andrew Knight said: "We are extremely pleased with the results of this study which demonstrate a high level of efficacy for our vaccine technology and reinforces our decision to transform Henderson Morley into a pure play vaccine company by 2011."

News of the results of the study sent Henderson Morley's share rocketing by 28.5%.

KHV, which is now officially known as Cyprinid Herpes Virus 3 (CyHV-3) is now a notifiable disease in the UK. It affects Koi and Common carp and has led to mass mortalities in fish stocks in the wild and in captivity around the world.